A Guide to the Management of Tuberculosis in Patients with Chronic Liver Disease

Journal of Clinical and Experimental Hepatology

Volumn 2, Issue 3, 2012, Pages 260-270

  Dhiman, Radha K ^a   Saraswat, Vivek A ^b   Rajekar, Harshal ^a   Reddy, Chandrasekhar ^a   Chawla, Yogesh K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti tuberculosis drugs; Cirrhosis; Hepatotoxicity; Treatment; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BCG VACCINE; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BCG VACCINATION; CAUSE OF DEATH; CHRONIC LIVER DISEASE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FATTY LIVER; FEVER; GRANULOMATOUS HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNE DEFICIENCY; INTERFERON GAMMA RELEASE ASSAY; INTRAHEPATIC CHOLESTASIS; JAUNDICE; LATENT TUBERCULOSIS; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; LYMPHOCYTIC INFILTRATION; MALAISE; MONOTHERAPY; NAUSEA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SIDE EFFECT; TOXIC HEPATITIS; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS LOAD; VOMITING;

EID: 84866550149     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2012.07.007     Document Type: Review

References (77)

1. Thulstrup A.M., Molle I., Svendsen N., Sorensen H.T. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect 2000, 124:221-225.
2. Baijal R., Praveenkumar H.R., Amarapurkar D.N., Nagaraj K., Jain M. Prevalence of tuberculosis in patients with cirrhosis of liver in western India. Trop Doct 2010, 40:163-164.
3. Wu H.P., Pan Y.H., Hua C.C., Shieh W.B., Jiang B.Y., Yu T.J. Pneumoconiosis and liver cirrhosis are not risk factors for tuberculosis in patients with pulmonary infection. Respirology 2007, 12:416-419.
4. Saigal S., Nandeesh H.P., Agarwal S.R., Misra A., Jain S.K., Sarin S.K. High prevalence and profile of tuberculosis in chronic liver disease patients. Gastroenterology 1998, 114:A38.
5. Jiang J.R., Yen S.Y., Wang J.Y. Increased prevalence of primary drug-resistant pulmonary tuberculosis in immunocompromised patients. Respirology 2011, 16:308-313.
6. Kim N.J., Choo E.J., Kwak Y.G., et al. Tuberculous peritonitis in cirrhotic patients: comparison of spontaneous bacterial peritonitis caused by Escherichia coli with tuberculous peritonitis. Scand J Infect Dis 2009, 41:852-856.
7. Hillebrand D.J., Runyon B.A., Yasmineh W.G., Rynders G.P. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology 1996, 24:1408-1412.
8. Reddy K.R., DiPrima R.E., Raskin J.B., et al. Tuberculous peritonitis: laparoscopic diagnosis of an uncommon disease in the United States. Gastrointest Endosc 1988, 34:422-426.
9. Dhiman R.K. Tuberculous peritonitis: towards a positive diagnosis. Dig Liver Dis 2004, 36:175-177.
10. Bonnel A.R., Bunchorntavakul C., Reddy K.R. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2011, 9:727-738.
11. Shawcross D.L., Wright G.A., Stadlbauer V., et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008, 48:1202-1212.
12. Laso F.J., Lapena P., Madruga J.I., et al. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Alcohol Clin Exp Res 1997, 21:1226-1231.
13. Cho H.J., Koh W.J., Ryu Y.J., et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007, 87:551-556.
14. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Phar-macokinet 1999, 37:399-431.
15. Gupta N.K., Lewis J.H. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008, 281021-281041.
16. Rajagopala S., Olithselvan A., Varghese J., Shanmugam N., Rela M. Latent Mycobacterium tuberculosis infection in liver transplant recipients - controversies in current diagnosis and management. J Clin Experimental Hepatol 2011, 34-37.
17. Benito N., Sued O., Moreno A., et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002, 74:1381-1386.
18. Mazurek G.H., Weis S.E., Moonan P.K., et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 2007, 45:837-845.
19. Manuel O., Humar A., Preiksaitis J., et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007, 7:2797-2801.
20. Gronhagen-Riska C., Hellstrom P.E., Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of Tuberculosis. Am Rev Respir Dis 1978, 118:461-466.
21. American Thoracic Society; CDC; Infectious Diseases Society of America Treatment of tuberculosis. MMWR Recomm Rep 2003 Jun 20, 52(RR-11):1-77.
22. Self T.H., Chrisman C.R., Baciewicz A.M., Bronze M.S. Isoniazid drug and food interactions. Am J Med Sci 1999, 317:304-311.
23. Senousy B.E., Belal S.I., Draganov P.V. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol 2010, 7:543-556.
24. Park W.B., Kim W., Lee K.L., et al. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect 2010, 61:323-329.
25. Padmapriyadarsini C., Chandrabose J., Victor L., Hanna L.E., Arunkumar N., Swaminathan S. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. J Postgrad Med 2006, 52:92-96.
26. Garibaldi R.A., Drusin R.E., Ferebee S.H., Gregg M.B. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972, 106:357-365.
27. Tostmann A., Boeree M.J., Aarnoutse R.E., de Lange W.C., van der Ven A.J., Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008, 23:192-202.
28. Fountain F.F., Tolley E., Chrisman C.R., Self T.H. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005, 128:116-123.
29. Steele M.A., Burk R.F., DesPrez R.M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991, 99:465-471.
30. Moulding T. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992, 146:1643-1644.
31. Verma S., Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009, 58:1555-1564.
32. Bass J.B., Farer L.S., Hopewell P.C., et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994, 149:1359-1374.
33. Bailey W.C., Weill H., DeRouen T.A., Ziskind M.M., Jackson H.A. The effect of isoniazid on transaminase levels. Ann Intern Med 1974, 81:200-202.
34. Comstock G.W. New data on preventive treatment with isoniazid. Ann Intern Med 1983, 98. 663-635.
35. McNeill L., Allen M., Estrada C., Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003, 123:102-106.
36. Millard P.S., Wilcosky T.C., Reade-Christopher S.J., Weber D.J. Isoniazid-related fatal hepatitis. West J Med 1996, 164:486-491.
37. Kopanoff D.E., Snider D.E., Caras G.J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978, 117:991-1001.
38. Salpeter S.R. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993, 159:560-564.
39. Gent W.L., Seifart H.I., Parkin D.P., Donald P.R., Lamprecht J.H. Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients. Eur J Clin Pharmacol 1992, 43:131-136.
40. Noda A., Hsu K.Y., Noda H., Yamamoto Y., Kurozumi T. Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine?. J UOEH 1983, 5:183-190.
41. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
42. American Thoracic Society/Centers for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161:S221-S247.
43. Byrne J.A., Strautnieks S.S., Mieli-Vergani G., Higgins C.F., Linton K.J., Thompson R.J. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002, 123:1649-1658.
44. Capelle P., Dhumeaux D., Mora M., Feldmann G., Berthelot P. Effect of rifampicin on liver function in man. Gut 1972, 13:366-371.
45. Menzies D., Dion M.J., Rabinovitch B., Mannix S., Brassard P., Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004, 170:445-449.
46. Zierski M., Bek E. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. Tubercle 1980, 61:41-49.
47. Salfinger M., Heifets L.B. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 1988, 32:1002-1004.
48. Ijaz K., Jereb J.A., Lambert L.A., et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2006, 42:346-355.
49. Snavely S.R., Hodges G.R. The neurotoxicity of antibacterial agents. Ann Intern Med 1984, 101:92-104.
50. Barth J., Jager D., Mundkowski R., Drewelow B., Welte T., Burkhardt O. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. J Antimicrob Chemother 2008, 62:575-578.
51. Dixit R.K., Satapathy S.K., Kumar R., et al. Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. Indian J Gastroenterol 2002, 21:62-63.
52. Esposito S., Noviello S., Leone S., Ianniello F., Ascione T., Gaeta G.B. Clinical efficacy and tolerability of levofloxacin in patients with liver disease: a prospective, non comparative, observational study. J Chemother 2006, 18:33-37.
53. Wolfson J.S., Hooper D.C. Overview of fluoroquinolone safety. Am J Med 1991, 91:153S-161S.
54. Schenker S., Martin R.R., Hoyumpa A.M. Antecedent liver disease and drug toxicity. J Hepatol 1999, 31:1098-1105.
55. Wong W.M., Wu P.C., Yuen M.F., et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000, 31:201-206.
56. McGlynn K.A., Lustbader E.D., Sharrar R.G., Murphy E.C., London W.T. Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis 1986, 134:666-668.
57. Lee B.H., Koh W.J., Choi M.S., et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005, 127:1304-1311.
58. Patel P.A., Voigt M.D. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002, 97:1198-2203.
59. Yu W.C., Lai S.T., Chiu M.C., Chau T.N., Ng T.K., Tam C.M. Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection. Int J Tuberc Lung Dis 2006, 10:824-825.
60. Sadaphal P., Astemborski J., Graham N.M., et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001, 33:1687-1691.
61. Ungo J.R., Jones D., Ashkin D., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998, 157:1871-1876.
62. Kwon Y.S., Koh W.J., Suh G.Y., Chung M.P., Kim H., Kwon O.J. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest 2007, 131:803-808.
63. Fernández-Villar A., Sopeña B., García J., et al. Hepatitis C virus RNA in serum as a risk factor for isoniazid hepatotoxicity. Infection 2007, 35:295-297.
64. Tsai M.C., Lin M.C., Hung C.H. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis. J Formos Med Assoc 2009, 108:746-750.
65. Lew W., Pai M., Oxlade O., Martin D., Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008, 149:123-134.
66. Mathur M.L., Khatri P.K., Base C.S. Drug resistance in tuberculosis patients in Jodhpur district. Indian J Med Sci 2000, 54:55-58.
67. Steele M.A., Des Prez R.M. The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988, 94:845-850.
68. Pilheu J.A., DeSalvo M.C., Koch O. Liver alterations in antituberculosis regimens containing Pyrazinamide. Chest 1981, 80:720-724.
69. Dhingra V.K. Treatment of tuberculosis in liver disease: A Clinician's view. Indian J Tuberc 2006, 53:232-233.
70. Garcia-Tsao G., Friedman S., Iredale J., Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010, 51:1445-1449.
71. Laleman W., Verbeke L., Meersseman P., et al. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol 2011, 5:523-537.
72. Mitchison D.A., Nunn A.J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986, 133:423-430.
73. United States Public Health Service Hepatic toxicity of pyrazinamide used with isoniazid in tuberculous patients. United States Public Health Service Tuberculosis Therapy Trial. Am Rev Respir Dis 1959, 80:371-387.
74. Saigal S., Agarwal S.R., Nandeesh H.P., Sarin S.K. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol 2001, 16:1028-1032.
75. Polson J.E. Hepatotoxicity due to antibiotics. Clin Liver Dis 2007, 11:549-561.
76. Kaneko Y., Nagayama N., Kawabe Y., et al. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis]. Kekkaku 2008, 83:13-19.
77. Ziakas P.D., Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009, 49:1883-1889.